Program
aumolertinib
Also written as “Almonertinib”, “Aumolertinib” and “HS-10296”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 85 open or running | phase 3since Nov 23, 2018 | Nov 28, 2016 | none ahead |
| Jiangsu HengRui Medicine | 43 open or running | phase 3since Sep 12, 2025 | Apr 2, 2019 | Jul 30, 2027phase 2 · NCT05503888 |
| EQRx International | 20 open or running | phase 3since Jun 24, 2022 | Nov 5, 2021 | none ahead |
| Revolution Medicines | 10 open or running | phase 1since Jul 13, 2021 | Jul 13, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 28, 2016First study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT02981108 · 364 enrolled · United States
- Nov 23, 2018Phase 3 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT03849768 · 429 enrolled · China
- Apr 2, 2019Jiangsu HengRui Medicine's first study: phase 2 study in EGFR-mutant Non-Small Cell Lung CancerNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT03904823 · 58 enrolled · China
- Dec 23, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT04687241 · 192 enrolled · China
- Jun 10, 20213 phase 3 studies in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT04923906, NCT04951648, NCT04951635
- Jul 13, 2021Revolution Medicines's first study: phase 1 study in NSCLCNew to Revolution MedicinesRevolution Medicines · NCT04969965 · 45 enrolled · United States, New Zealand
- Nov 5, 2021EQRx International's first study: phase 1 study in Severe Hepatic ImpairmentNew to EQRx InternationalEQRx International · NCT05199610 · 12 enrolled · United States
- Jun 24, 2022Phase 3 study in NSCLCEQRx International · NCT05493501 · 8 enrolled · United States
- Aug 8, 2022Phase 2 study in RecurrenceJiangsu HengRui Medicine · NCT05503888 · 160 planned
- Oct 24, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT06110663 · 314 planned
- Jul 31, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT07130916 · 20 planned · Bosnia and Herzegovina, Bulgaria, Moldova
- Sep 12, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT07183189 · 582 enrolled · China
- Sep 30, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT07863167 · 660 planned · China
Ahead
- Jul 30, 2027Primary completion: phase 2 study in RecurrenceJiangsu HengRui Medicine · NCT05503888
- Dec 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT07863167
- Nov 2032Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT07183189
TargetBeta
“An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07863167Carcinoma, Non-Small-Cell Lung · China | 2 | Not yet recruiting | Jiangsu HengRui Medicine | Dec 30, 2028 | 660 |
| NCT07183189Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Jiangsu HengRui Medicine | Nov 2032 | 582 |
| NCT07130916Carcinoma, Non-Small-Cell Lung · Bosnia and Herzegovina, Bulgaria, Moldova | 1 | Recruiting | Hansoh Pharmaceutical Group | Aug 9, 2025 | 20 |
| NCT06110663Carcinoma, Non-Small-Cell Lung | 3 | Not yet recruiting | Hansoh Pharmaceutical Group | Dec 30, 2024 | 314 |
| NCT05503888Recurrence | 2 | Not yet recruiting | Jiangsu HengRui Medicine | Jul 30, 2027 | 160 |
| NCT05493501NSCLC · United States | 3 | Terminated | EQRx International | Aug 31, 2023 | 8 |
| NCT05199610Severe Hepatic Impairment · United States | 1 | Completed | EQRx International | Apr 1, 2023 | 12 |
| NCT04969965NSCLC · United States, New Zealand | 1 | Completed | Revolution Medicines | Oct 7, 2021 | 45 |
| NCT04951648Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Hansoh Pharmaceutical Group | Oct 4, 2023 | 220 |
| NCT04951635Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Hansoh Pharmaceutical Group | Jul 15, 2024 | 150 |
| NCT04923906Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Hansoh Pharmaceutical Group | Jun 18, 2024 | 624 |
| NCT04687241Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Hansoh Pharmaceutical Group | Jul 8, 2024 | 192 |
| NCT03904823EGFR-mutant Non-Small Cell Lung Cancer · China | 2 | UNKNOWN | Jiangsu HengRui Medicine | Dec 2022 | 58 |
| NCT03849768Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Hansoh Pharmaceutical Group | Jan 15, 2021 | 429 |
| NCT02981108Carcinoma, Non-Small-Cell Lung · United States | 2 | UNKNOWN | Hansoh Pharmaceutical Group | Jan 5, 2019 | 364 |
How it is read
Names in the registry
- “Almonertinib”, 3 entries
- “Aumolertinib”, 2 entries
- “aumolertinib”, 2 entries
- “HS-10296”, 2 entries
- “almonertinib”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 11 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.